Why mucosal immunity may be required to end the pandemic
Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.
Following the recent emergency use authorizations of multiple vaccines for COVID-19, the first wave of people have already begun the vaccination process — a truly remarkable milestone. As someone who has dedicated his career to drug development and discovery focused on viral vectors and antiviral therapies, I can tell you that the science has moved fast, and we have every reason to celebrate. The data on these vaccines are good. They are well studied and their potential for public health is promising.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.